In January 2021, Combined Therapeutics began working with the Precisions Vaccine Program (PVP) at Boston Children’s Hospital – Harvard Medical School to evaluate our mRNA-based molecular adjuvants in their preclinical vaccine models.
![logo-bch-primary-tag-300dpi](https://www.combinedtx.com/wp-content/uploads/2023/07/logo-bch-primary-tag-300dpi.png)
Partner with Us
If you are interested in partnering with Combined Therapeutics, complete and submit the form below.
![ORF_2 (1)](https://www.combinedtx.com/wp-content/uploads/2023/07/ORF_2-1.gif)